louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00524355: Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
Official title: Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of the Gastroesophageal Reflux Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: GERD
Keywords: GERD
GIS
heartburn
NIS
PPI
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-09-03
Enrollment: 2717
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: primary care clinics, private clinics and out-patient department at hospitals in cities and provinces of Viet Nam

Brief summary: To describe the frequency, type and severity of the symptoms in patients visiting the GI or internal physicians, with symptoms consistent with gastroesophageal reflux disease (GERD)


Eligibility criteria: Inclusion Criteria:

* Patients from both sexes, aged 18 years or older
* Patients complaining of symptoms consistent with reflux disease

Exclusion Criteria:

* Patients with GI cancer and those where the only reason for the visit is renewing the prescription are excluded

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hanoi
country: Vietnam
facility: Research Site
city: Ho Chi Minh City
country: Vietnam
facility: Research Site
Study officials:
affiliation: 108 Hospital, Hanoi
name: Ta Long, MD, PhD
role: STUDY_CHAIR
affiliation: Ho Chi Minh City Univ of Medicine and Pharmacist
name: Do Van Dung, MD, PhD
role: STUDY_CHAIR
affiliation: Ha Noi University of Medicine Hospital
name: Dao Van Long, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00269555: Effects of GCP on Prostate Cancer.
Official title: Effects of a Genistein Combined Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Keywords: Prostate
Cancer
Prostate Specific Antigen
C04.588.945.440.770
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2005-12-23
Enrollment: 62
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Genistein Combined Polysaccharide (GCP) is derived from adding soy powder to shiitake mushrooms. This concentrated mixture is currently being sold in Japan and the United States and is thought to possibly contain properties that may be useful in treating certain types of cancer.


Eligibility criteria: Inclusion Criteria:

Participants must be male and have a pathological diagnosis of prostate cancer.

No treatment (surgery \[RRP\], radiation, or hormones) prior to study entry.

The patient has decided, after consultation with his own doctor, to have no treatment intervention (surgery \[RRP\], radiation, or hormones) for the next six months.

PSA between 2.0 and 10.0 ng/ml.

If PSA is \>10.0, patient must have been on Active Surveillance for 12 months prior to study initiation.

No known allergy to soy or soy products.

The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements).

-

Exclusion Criteria:

No pathological documentation of prostate cancer.

Allergy to soy or soy products

Prior history of treatment for prostate cancer.

-

Primary outcomes:
measure: Reduction in PSA serum levels.
Secondary outcomes:
measure: Stabilization of PSA serum levels.
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Robert Hackman, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, Davis
name: Ralph W deVere White, MD
role: STUDY_DIRECTOR
References:
citation: deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004 Feb;63(2):259-63. doi: 10.1016/j.urology.2003.09.061.
Clinical trial NCT02049255: Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.
Official title: Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: All
Lead sponsor: Astes
Sponsor class: OTHER
First posted: 2014-01-30
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison the use of marcaine and chloroprocaine in rachianesthesia for a surgical correction of inguinal hernia. Comparision between acute and chronic (3 months and 6 months) pain.


Eligibility criteria: Inclusion Criteria:

* Adults under rachianesthesia

Exclusion Criteria:

* Personal history of gastric ulcus
* ASA 4
* Emergency
* Combined surgery

Primary outcomes:
measure: Acute pain
timeFrame: 1 day of the surgery when patient leave the recovery room
Secondary outcomes:
measure: Chronic pain
timeFrame: at 3 and 6 months
Other outcomes:
Locations:
city: Bouge
country: Belgium
facility: Clinique Saint-Luc Bouge
state: Namur
Study officials:
affiliation: Astes
name: Eric P Deflandre, MD, FCCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00322855: Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma
Official title: Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Sarcoma
Lead sponsor: New Mexico Cancer Research Alliance
Sponsor class: OTHER
First posted: 2006-05-08
Enrollment: 1
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with soft tissue sarcoma treated with chemotherapy form 2004 and 2005.

Brief summary: To review the outcome of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005.

Detailed description: Chart review of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005 to determine outcome

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with soft tissue sarcoma treated with chemotherapy form 2004 and 2005.

Exclusion Criteria:

* Not Specified

Primary outcomes:
measure: To Review the Outcome of Patients With Soft Tissue Sarcoma Treated With Chemotherapy From 2004 and 2005
timeFrame: up to one year
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Aroop Mangalik, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06248255: Impact on Elderly Skin Due to Wet Pad Application.
Official title: Impact to Skin Due to Wet Pad Application. Skin Status and Change in the Stratum Corneum as Measured With 4 Instruments in an Elderly Population.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Incontinence
Lead sponsor: Essity Hygiene and Health AB
Sponsor class: INDUSTRY
First posted: 2024-02-08
Enrollment: 24
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The test pads is to both forearms of the participants. Participants will be blinded to the test pad type. In total 4 pads are applied per participant. The test pads are either Dry (control), 50% or at 100% capacity. Dry and 50% pads are applied once, 100% capacity twice. This to allow one pad for recovery measurement and one for water profile measurement. Pad location will be randomized.
Primary purpose: BASIC_SCIENCE

Brief summary: The clinical study aims to measure the changes in the stratum corneum on older healthy participants due to the application of a wet pad on the forearm. Participants are subject to baseline measures of TransEpidermalWaterLoss (TEWL), skin hydration (SH), pH and water profile (raman spectroscopy). Dry or wet pads are then added to the skin and worn for two hours. After a recovery period, the SkinSurfaceWaterLoss (SSWL) and skin hydration and water profile is measured. The study is conducted over a single visit. Pads on the arms consist of incontinence product cutouts and are loaded to 50% or 100% capacity. The endpoints are the changes in stratum corneum as measured by the instruments during the visit.


Eligibility criteria: Inclusion Criteria:

1. Men and women ≥ 65 years.
2. Mentally and physically able to participate in this study.
3. Written informed consent to participate in this study.
4. Intact skin on the volar forearms without skin irritation.

Exclusion Criteria:

1. Have any known allergies or intolerances to one or several components of the absorbing incontinence product.
2. Suffer from excessive sweating, hyperhidrosis.
3. Have any other condition that makes participation in the clinical investigation inappropriate, as judged by investigator.
4. Not be of childbearing potential.
5. Have an alcohol and/or drug dependency.

Primary outcomes:
measure: Change Trans Epidermal Water loss
timeFrame: 2 hours
measure: Change in skin hydration
timeFrame: 2 hours
measure: Change in Skin water profile
timeFrame: 2 hours
Secondary outcomes:
measure: Change in skin surface pH
timeFrame: 2 hours
Other outcomes:
Locations:
city: Mölndal
country: Sweden
facility: Essity Study Site
Study officials:
affiliation: Essity Hygiene and Health AB
name: Shabira Abbas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03544255: Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
Official title: Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pancreatic Cancer
Pancreas Adenocarcinoma
Keywords: pancreatic cancer
EUS-FNA
organoid
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor class: OTHER
First posted: 2018-06-01
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suspected to have pancreatic cancer who are going to receive EUS-FNA operations for diagnostic purposes.

Brief summary: We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.

Detailed description: The survival rate of pancreatic cancer, a kind of malignant tumor, remains poor due to lack of effective treatments. Recently, a new model called "organoid" has been generated from human and murine pancreatic cancer tissues. These organoids are developed from large pieces of surgical tissues or small biopsies taken from EUS-FNA guided samples. Here in our study we are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. After successful generation of these organoids, we will treat them with the selected FDA-approved anti-cancer drugs, and assess the responses to these anti-cancer agents in our established organoids.

Eligibility criteria: Inclusion Criteria:

* 1) Patients suspected to have pancreatic cancer who will receive EUS-FNA for diagnosis; 2) Patients who have signed the informed consent.

Exclusion Criteria:

* 1) Those who are under the age of 18; 2) Patients who have received adjuvant chemoradiotherapies or other anti-tumor therapies; 3) Patients with critical illness and cannot tolerate the operations; 4) Women who have been pregnant or are planning to be pregnant.

Primary outcomes:
measure: Number of organoids successfully generated from pancreatic cancer biopsies
timeFrame: 09/01/2018-06/01/2019
Secondary outcomes:
measure: Response of the pancreatic cancer organoids to the selected anti-cancer drugs
timeFrame: 06/01/2019-06/01/2020
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School
state: Jiangsu
Study officials:
affiliation: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: Ying Lv, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01330355: Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Official title: Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Bacterial Conjunctivitis
Keywords: Ocular infections, bacterial
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2011-04-06
Enrollment: 33
Sex: ALL
Minimum age (years): 1
Maximum age (years): 31
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days to neonatal subjects who are 31 days or younger on the day of randomization (Visit 1).


Eligibility criteria: Inclusion Criteria:

* Subjects who have a clinical diagnosis of acute bacterial conjunctivitis and exhibit conjunctival discharge and redness in at least one eye. A minimum score of 1 should be present for discharge and a minimum score of 1 for conjunctival hyperemia in the same eye.

Exclusion Criteria:

* Subjects with conjunctivitis signs and/or symptoms suggestive of fungal, protozoal, or viral etiology in either eye.
* Subjects who require or are expected to require (other than study medication) use of any topical ocular medication in either eye, or systemic medications during the course of the study or prior to Day 1 specified in the protocol as ineligible.
* Subjects with any abnormality of the ocular anatomy or ocular disease/disorder specified in the protocol as ineligible.
* Subjects with systemic disease/disorder specified in the protocol as ineligible.
* Subjects who have a known or suspected poor tolerance, sensitivity, or allergy to the study medications or any of their components.
* Subjects who have a condition or are in a situation which in the investigator's opinion may impact their safety or would negatively affect the conduct or outcome of the study.

Primary outcomes:
measure: Clinical Resolution
timeFrame: Visit 5 (Day 8+1)
Secondary outcomes:
measure: Clinical Resolution
timeFrame: Visit 3 (Day 3)
measure: Microbial Eradication
timeFrame: Visit 5 (Day 8+1)
measure: Microbial Outcome
timeFrame: Visit 3 (Day 3) and Visit 5 (Day 8+1)
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Bausch & Lomb Incorporated
state: New Jersey
Study officials:
affiliation: Valeant/Bausch & Lomb
name: Johnson Varughese
role: STUDY_DIRECTOR
References:
Clinical trial NCT06396455: Ultrasound Guided Suprascapular Nerve Block Versus ISB Block in Arthroscopic Shoulder Surgery
Official title: A Comparison Between Ultrasound Guided Suprascapular Nerve Block Versus Ultrasound Guided Interscalene Brachial Plexus Block on Respiratory Mechanics in Patients Undergoing Arthroscopic Shoulder Surgery: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Surgery
Keywords: Anterior Suprascapular Nerve Block
Suprascapular Nerve Block
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2024-05-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group ISB (interscalene block group) received an ultrasound guided interscalene approach of brachial plexus plane block and group SSNB (suprascapular nerve block) received ultrasound guided suprascapular nerve block.
Primary purpose: PREVENTION

Brief summary: Diaphragmatic dysfunction can be detected as a decrease in forced vital capacity (FVC) and forced expiratory volume at 1 s (FEV1) on spirometry or as lower diaphragmatic excursion (DE) on US, the latter having become the gold standard in thoracic assessment.

Detailed description: Severe intraoperative and postoperative pain associated with arthroscopic shoulder surgery has high incidence reaching up to 45%; it is often significant enough to interfere with initial recovery and rehabilitation.

Shoulder arthroscopy is becoming more common, representing the second most common Orthopedic surgery after knee arthroscopy . Interscalene brachial plexus block (ISB) is the gold standard analgesic technique for shoulder surgeries with success rates of 87% to 100%, but it also blocks the phrenic nerve (C3-C5).

Suprascapular nerve block via the anterior approach (SSB-A) is performed distally at the trunk/division level of the brachial plexus, thereby potentially sparing the phrenic nerve and minimising many adverse effects of ISB

Eligibility criteria: Inclusion Criteria:

* aged (18-65 years)
* American Society of Anesthesiologists (ASA) physical status I or II
* scheduled for elective arthroscopic shoulder surgery

Exclusion Criteria:

* pre-existing respiratory,
* cardiac, renal, neurological, or hepatic disease, neuropathy affecting brachial plexus
* contraindication to peripheral nerve block (e.g., coagulopathy),

Primary outcomes:
measure: visual analogue score
timeFrame: Postoperative pain was assessed using VAS at Postoperative care unit, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24hours after block administration postoperatively
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Banha
country: Egypt
facility: Benha University
Study officials:
affiliation: Anesthesia and surgical ICU department, Faculty of Medicine, Benha University, Egypt
name: Ramy Saleh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06720155: Sleeper Stretch in CrossFit Participants
Official title: The Effects of a Sleeper Stretch Intervention on Measures of Performance and Pain in CrossFit Participants: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shoulder Pain
Keywords: CrossFit
Sleeper stretch
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of the sleeper stretch in improving shoulder range of motion, strength and upper body performance in CrossFit athletes.


Eligibility criteria: Inclusion Criteria:

• Regularly active (attending CrossFit \> 2x per week)

Exclusion Criteria:

* Positive test for labral lesions or rotator cuff tears
* History of recent fracture
* Orthopedic surgery in the upper limbs or cervical region
* Any other current injury that would prevent participation in regular work-shift activities

Primary outcomes:
measure: Upper body function
timeFrame: Baseline, 4 weeks, 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: La Crosse
country: United States
facility: Mayo Clinic Health System-La Crosse
state: Wisconsin
city: Onalaska
country: United States
facility: Driftless CrossFit
state: Wisconsin
Study officials:
affiliation: Mayo Clinic
name: Alecia Gende, DO, CAQSM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03446755: Use of an Intra Uterine Balloon to Prevent Recurrent Adhesions (REpAIR)
Official title: The Use of an Intrauterine Balloon in Preventing Adhesion Recurrence After Hysteroscopic Adhesiolysis: a Feasibility Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adhesion; Uterus, Internal
Keywords: antiadhesion treatment
Asherman's syndrome
hysteroscopic adhesiolysis
intrauterine adhesions
intrauterine balloon
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2018-02-27
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: To evaluate the feasibility of a hearth shaped intrauterine balloon as antiadhesion method subsequent to a hysteroscopic adhesiolysis in terms of surgeon's and patient's experience.
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Patients suffering of subfertility as a consequence of intrauterine adhesions could be treated with hysteroscopic adhesiolysis. Adhesion recurrence may occur postoperative. An intrauterine balloon, inserted after hysteroscopic adhesiolysis, may prevent adhesion reformation.

A Foley catheter can serve for this purpose, but its not ideal. COOK medical® developed a hearth shaped intrauterine balloon to reduce bleeding after intrauterine surgery.

We aimed to perform a pilot study of 10 procedures with insertion of a hearth shaped intrauterine balloon as antiadhesion method subsequent to a hysteroscopic adhesiolysis, to study its feasibility in terms of surgeon's and patient's experience.


Eligibility criteria: Inclusion Criteria:

* patients with intra uterine adhesions scheduled for hysteroscopic adhesiolysis

Primary outcomes:
measure: The number of recurrent adhesions after adhesiolysis
timeFrame: 5-10 weeks after adhesiolysis
measure: The number of complications after adhesiolysis
timeFrame: 5-10 weeks after adhesiolysis
Secondary outcomes:
measure: Pain after placement of the intra uterine balloon
timeFrame: 1 to 6 days after adhesiolysis
measure: Complications after placement of the intra uterine balloon
timeFrame: 1 to 6 days after adhesiolysis
measure: Pain at the time of the removal of the intra uterine balloon
timeFrame: 6 days after adhesiolysis
measure: Patient Satisfaction after removal of the intra uterine balloon
timeFrame: 6 days after adhesiolysis
measure: Malaise after placement of the intra uterine balloon
timeFrame: 6 days after adhesiolysis
measure: Daily functioning after placement of the intra uterine balloon (absence from work, impact on work productivity, impact on household, physical activity, daily life)
timeFrame: 6 days after adhesiolysis
measure: The ease of inserting the intra uterine balloon
timeFrame: once at the time of the surgical procedure (adhesiolysis). This is day 0 of the study
measure: The ease of removing the intra uterine balloon
timeFrame: 6 days after adhesiolysis
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University hospital Ghent
state: East-Flanders
Study officials:
References: